-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, news about the resignation of pharmaceutical company executives has been constant
.
Recently, several pharmaceutical companies have announced the resignation of senior executives in just one day
.
On October 14, Warner Pharmaceuticals issued an announcement stating that Li Mengchun had applied for resignation as director, deputy general manager, and secretary of the board of directors due to job changes
.
After resigning from the above-mentioned position, Li Mengchun will take on other jobs in the company
.
According to the relevant provisions of the "Company Law" and the "Articles of Association", Mr.
Li Mengchun's resignation report took effect from the day it was delivered to the company's board of directors
.
During the vacancy of the board secretary, the company's board of directors designates Ms.
Dou Lin, the deputy general manager and securities affairs representative, to act as the board secretary for no more than three months
.
It is worth noting that after resigning from the above-mentioned position, Mr.
Li Mengchun will also undertake other tasks in the company
.
Coincidentally, on the same day, Fangsheng Pharmaceutical also issued an announcement stating that it had received a written resignation report from the company’s independent director, Ms.
Liu Shuping
.
Due to personal work reasons, Ms.
Liu Shuping applied to resign as an independent director of the company's fifth board of directors and corresponding positions in the special committees under it
.
After resignation, he will no longer hold any position in the company
.
Analysts believe that the frequent wave of resignations in the pharmaceutical industry is the norm in the industry
.
According to incomplete statistics, since the second half of this year alone, 50 senior executives from more than 40 pharmaceutical companies have resigned, that is, involving Hengrui Pharmaceuticals, Hisun Pharmaceuticals, North China Pharmaceuticals, Guangshengtang, Yan'an Bikang and other local companies.
In addition to pharmaceutical companies, foreign pharmaceutical companies such as Eli Lilly, AstraZeneca, Novo Nordisk, and Roche Pharmaceuticals are also involved
.
Among them, it is worth mentioning that some time ago, GlaxoSmithKline China announced the resignation of two senior executives, Wang Xinguang, vice president, head of China’s corporate communications and government affairs, and Chen Ming, vice president and head of registration affairs.
, And attracted the attention of the industry
.
At present, from an overall point of view, deputy general managers and directors resign intensively, and the reasons for resignation are mainly "personal reasons"
.
In this regard, the industry believes that in the current changing situation of the pharmaceutical market, pharmaceutical companies will continue to make strategic adjustments in order to respond to market changes.
.
Affected by this, the flow of talents in the pharmaceutical market will also continue
.
However, this is not entirely a bad thing.
For medical workers with strength, experience, and professional abilities, it may be an opportunity
.
Because judging from the current job-hopping salary increase rate and turnover rate, the pharmaceutical industry still has a strong demand for talents and is willing to attract job seekers with higher salary increases than other industries
.
In short, it is not uncommon for high-level executives to leave frequently in the pharmaceutical industry, and the reasons behind it are mainly closely related to changes in the industry environment
.
The industry predicts that in the future, with the continuous advancement of policies such as medical insurance control fees, volume purchases, medical insurance negotiations, and consistency evaluations, in the process of forcing companies to actively innovate and transform, personnel changes in the pharmaceutical industry and the delisting of pharmaceutical companies will occur.
It will also become more and more common
.
As for the relevant staff, in this context, they can only improve their competitiveness by continuously improving their professional capabilities
.
.
Recently, several pharmaceutical companies have announced the resignation of senior executives in just one day
.
On October 14, Warner Pharmaceuticals issued an announcement stating that Li Mengchun had applied for resignation as director, deputy general manager, and secretary of the board of directors due to job changes
.
After resigning from the above-mentioned position, Li Mengchun will take on other jobs in the company
.
According to the relevant provisions of the "Company Law" and the "Articles of Association", Mr.
Li Mengchun's resignation report took effect from the day it was delivered to the company's board of directors
.
During the vacancy of the board secretary, the company's board of directors designates Ms.
Dou Lin, the deputy general manager and securities affairs representative, to act as the board secretary for no more than three months
.
It is worth noting that after resigning from the above-mentioned position, Mr.
Li Mengchun will also undertake other tasks in the company
.
Coincidentally, on the same day, Fangsheng Pharmaceutical also issued an announcement stating that it had received a written resignation report from the company’s independent director, Ms.
Liu Shuping
.
Due to personal work reasons, Ms.
Liu Shuping applied to resign as an independent director of the company's fifth board of directors and corresponding positions in the special committees under it
.
After resignation, he will no longer hold any position in the company
.
Analysts believe that the frequent wave of resignations in the pharmaceutical industry is the norm in the industry
.
According to incomplete statistics, since the second half of this year alone, 50 senior executives from more than 40 pharmaceutical companies have resigned, that is, involving Hengrui Pharmaceuticals, Hisun Pharmaceuticals, North China Pharmaceuticals, Guangshengtang, Yan'an Bikang and other local companies.
In addition to pharmaceutical companies, foreign pharmaceutical companies such as Eli Lilly, AstraZeneca, Novo Nordisk, and Roche Pharmaceuticals are also involved
.
Among them, it is worth mentioning that some time ago, GlaxoSmithKline China announced the resignation of two senior executives, Wang Xinguang, vice president, head of China’s corporate communications and government affairs, and Chen Ming, vice president and head of registration affairs.
, And attracted the attention of the industry
.
At present, from an overall point of view, deputy general managers and directors resign intensively, and the reasons for resignation are mainly "personal reasons"
.
In this regard, the industry believes that in the current changing situation of the pharmaceutical market, pharmaceutical companies will continue to make strategic adjustments in order to respond to market changes.
.
Affected by this, the flow of talents in the pharmaceutical market will also continue
.
However, this is not entirely a bad thing.
For medical workers with strength, experience, and professional abilities, it may be an opportunity
.
Because judging from the current job-hopping salary increase rate and turnover rate, the pharmaceutical industry still has a strong demand for talents and is willing to attract job seekers with higher salary increases than other industries
.
In short, it is not uncommon for high-level executives to leave frequently in the pharmaceutical industry, and the reasons behind it are mainly closely related to changes in the industry environment
.
The industry predicts that in the future, with the continuous advancement of policies such as medical insurance control fees, volume purchases, medical insurance negotiations, and consistency evaluations, in the process of forcing companies to actively innovate and transform, personnel changes in the pharmaceutical industry and the delisting of pharmaceutical companies will occur.
It will also become more and more common
.
As for the relevant staff, in this context, they can only improve their competitiveness by continuously improving their professional capabilities
.
